Campbell & CO Investment Adviser LLC Ironwood Pharmaceuticals Inc Transaction History

Campbell & CO Investment Adviser LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.32 - $15.45 $247,170 - $458,988	29,708 New	29,708 $258,000
Q2 2023 Aug 11, 2023	SELL	$10.1 - $11.6 $46,207 - $53,070	-4,575 Reduced 18.33%	20,384 $216,000
Q1 2023 May 11, 2023	SELL	$10.37 - $12.56 $117,886 - $142,782	-11,368 Reduced 31.29%	24,959 $262,000
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $221,195 - $277,723	22,343 Added 159.78%	36,327 $450,000
Q3 2022 Nov 14, 2022	SELL	$10.14 - $12.38 $301,249 - $367,797	-29,709 Reduced 67.99%	13,984 $145,000
Q2 2022 Aug 09, 2022	BUY	$11.05 - $12.72 $482,807 - $555,774	43,693 New	43,693 $504,000
Q1 2022 May 09, 2022	SELL	$10.61 - $12.88 $199,637 - $242,350	-18,816 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$10.86 - $13.95 $52,128 - $66,960	-4,800 Reduced 20.33%	18,816 $219,000
Q3 2021 Nov 10, 2021	BUY	$11.92 - $13.92 $136,484 - $159,384	11,450 Added 94.11%	23,616 $308,000
Q2 2021 Aug 11, 2021	BUY	$10.16 - $13.11 $123,606 - $159,496	12,166 New	12,166 $157,000
Q1 2021 May 14, 2021	SELL	$9.04 - $11.86 $116,308 - $152,590	-12,866 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$9.05 - $12.2 $116,437 - $156,965	12,866 New	12,866 $147,000
Q3 2020 Oct 15, 2020	SELL	$8.99 - $10.74 $104,967 - $125,400	-11,676 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$9.14 - $11.97 $106,718 - $139,761	11,676 New	11,676 $120,000
Q4 2018 Feb 08, 2019	SELL	$7.8 - $16.13 $105,300 - $217,755	-13,500 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$14.31 - $17.65 $193,185 - $238,274	13,500 New	13,500 $249,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.